Therefore, a comprehensive understanding of the biphasic role of STING pathway activation in curbing cancer progression is necessary, and clearer treatment protocols and availability of patient‐selective biomarkers for individual tumor types able to indicate which those patients for whom STING activation will be therapeutically beneficial are still needed. This evidence concerns the gene STING1 and cancer.